Page 98 - AN-3-4

Advanced Neurology SARS-CoV-2 in age-associated neurodegeneration

128. Abd El-Aziz TM, Al-Sabi A, Stockand JD. Human doi: 10.1038/s41591-022-02074-w
recombinant soluble ACE2 (hrsACE2) shows promise for 134. Hanson BA, Visvabharathy L, Ali ST, et al. Plasma
treating severe COVID-19. Signal Transduct Target Ther. biomarkers of neuropathogenesis in hospitalized patients
2020;5(1):258.
with COVID-19 and those with postacute sequelae
doi: 10.1038/s41392-020-00374-6 of SARS-CoV-2 infection. Neurol Neuroimmunol
Neuroinflamm. 2022;9(3):e1151.
129. Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA.
The role of IL-6 and other mediators in the cytokine storm doi: 10.1212/NXI.0000000000001151
associated with SARS-CoV-2 infection. J Allergy Clin 135. Altmann DM, Whettlock EM, Liu S, Arachchillage DJ,
Immunol. 2020;146(3):518-534.e1.
Boyton RJ. The immunology of long COVID. Nat Rev
doi: 10.1016/j.jaci.2020.07.001 Immunol. 2023;23(10):618-634.
130. Zhang X, Shang L, Fan G, et al. The efficacy and safety of doi: 10.1038/s41577-023-00904-7
Janus kinase inhibitors for patients with COVID-19: A living
systematic review and meta-analysis. Front Med (Lausanne). 136. Merad M, Subramanian A, Wang TT. An aberrant
2022;8:800492. inflammatory response in severe COVID-19. Cell Host
Microbe. 2021;29(7):1043-1047.
doi: 10.3389/fmed.2021.800492
doi: 10.1016/j.chom.2021.06.018
131. Patel S, Wadhwa M. Therapeutic use of specific tumour
necrosis factor inhibitors in inflammatory diseases including 137. Gusev E, Sarapultsev A, Solomatina L, Chereshnev V.
COVID-19. Biomed Pharmacother. 2021;140:111785. SARS‐COV‐2‐specific immune response and the
pathogenesis of COVID‐19. Int J Mol Sci. 2022;23(3):1716.
doi: 10.1016/j.biopha.2021.111785
doi: 10.3390/ijms23031716
132. Wilhelm G, Mertowska P, Mertowski S, et al. The
crossroads of the coagulation system and the immune 138. Leblanc P, Vorberg IM. Viruses in neurodegenerative
system: Interactions and connections. Int J Mol Sci. diseases: More than just suspects in crimes. PLoS Pathog.
2023;24(16):12563. 2022;18(8):e1010670.
doi: 10.1371/journal.ppat.1010670
doi: 10.3390/ijms241612563
139. Rohaim MA, El Naggar RF, Clayton E, Munir M. Structural
133. Ashton NJ, Janelidze S, Mattsson-Carlgren N, et al.
Differential roles of Aβ42/40, p-tau231 and p-tau217 for and functional insights into non-structural proteins of
Alzheimer’s trial selection and disease monitoring. Nat Med. coronaviruses. Microb Pathog. 2021; 150:104641.
2022;28(12):2555-2562. doi: 10.1016/j.micpath.2020.104641

Volume 3 Issue 4 (2024) 25 doi: 10.36922/an.4267